MDA-MB-175-VIIHomo sapiens (Human)Cancer cell line

Also known as: MD Anderson-Metastatic Breast-175-VII, MDA175, MDA-175, MDAMB175, MDA-MB-175, MDAMB175VII, MDA-MB-175VII, MDA MB 175 VII

🤖 AI SummaryBased on 15 publications

Quick Overview

Human breast cancer cell line with specific genetic alterations.

Detailed Summary

MDA-MB-175-VII is a human breast cancer cell line derived from a patient with invasive mucinous adenocarcinoma. It is characterized by a DOC4-NRG1 fusion, which has been confirmed through RT-PCR. This cell line is used in research to study the effects of ERBB3 and ERBB2 inhibition, as well as the role of NRG1 rearrangements in cancer progression. The cell line has been utilized in studies examining the efficacy of targeted therapies such as GSK2849330, an anti-ERBB3 monoclonal antibody, and afatinib, an ERBB2 inhibitor. Additionally, it has been part of genomic and transcriptomic analyses to understand the molecular mechanisms underlying cancer development and drug resistance.

Research Applications

Study of ERBB3 and ERBB2 inhibitionInvestigation of NRG1 rearrangements in cancer progressionEvaluation of targeted therapies like GSK2849330 and afatinibGenomic and transcriptomic analyses for cancer mechanisms and drug resistance

Key Characteristics

DOC4-NRG1 fusionUsed in studies on ERBB3/ERBB2 inhibitionPart of genomic profiling for cancer research
Generated on 6/16/2025

Basic Information

Database IDCVCL_1400
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age56
Age CategoryAdult
SexFemale
Raceblack_or_african_american
Subtype FeaturesER+, PR+, HER2+

Disease Information

DiseaseInvasive breast carcinoma of no special type
LineageBreast
SubtypeBreast Invasive Ductal Carcinoma
OncoTree CodeIDC

DepMap Information

Source TypeATCC
Source IDACH-000759_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
Gene fusionNRG1TENM4-NRG1, DOC4-NRG1-In framePubMed=29610121, PubMed=12800145

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
7,8
D13S317
11,12
D16S539
11,13
D18S51
15
D19S433
12.2,15
D21S11
29,30
D2S1338
22
D3S1358
16,18
D5S818
11
D7S820
11,12
D8S1179
14,17
FGA
23,26
Penta D
3.2
Penta E
8,15
TH01
7
TPOX
6,8
vWA
15,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers.

Matheny C., Benayed R., Rekhtman N., Ladanyi M., Ganji G.

Cancer Discov. 8:686-695(2018).

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Lakhani S.R.

Breast Cancer Res. Treat. 167:289-301(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

McCormick F., Gray J.W.

Cancer Cell 24:450-465(2013).

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Martens J.W.M.

Breast Cancer Res. 15:R33.1-R33.17(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Is HPV-18 present in human breast cancer cell lines?";

Peran I., Riegel A.T., Dai Y., Schlegel R., Liu X.

Br. J. Cancer 102:1549-1550(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Yamamoto S., Oka M., Hirano T., Sasaki K.

BMC Cancer 10:15.1-15.10(2010).

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.

Breast Cancer Res. Treat. 121:53-64(2010).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

Cancer Cell 10:515-527(2006).

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

Breast Cancer Res. Treat. 99:97-101(2006).

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

Cancer Res. 66:41-45(2006).

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Edwards P.A.W., Caldas C.

Carcinogenesis 26:923-930(2005).

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Edwards P.A.W., Chaffanet M.

Genes Chromosomes Cancer 37:333-345(2003).

Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.

Birnbaum D., Chaffanet M.

Genes Chromosomes Cancer 35:204-218(2002).

Molecular cytogenetic analysis of breast cancer cell lines.";

Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.

Br. J. Cancer 83:1309-1317(2000).

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Cancer Res. 60:4519-4525(2000).

Breast tumor cell lines from pleural effusions.";

Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.

J. Natl. Cancer Inst. 53:661-674(1974).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

Cailleau R.M., Olive M., Cruciger Q.V.J.

In Vitro 14:911-915(1978).

Cell lines from human breast.";

Leibovitz A.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).